Source:http://linkedlifedata.com/resource/pubmed/id/15627886
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5-6
|
| pubmed:dateCreated |
2005-1-3
|
| pubmed:abstractText |
The tyrosine-kinase receptor c-kit (CD117) and its ligand stem cell factor are considered to be co-expressed in various solid tumors, including adenocarcinomas of the lung. The frequency of c-kit expression and its association with clinical parameters has not yet been evaluated in a larger population of lung adenocarcinomas. Therefore, tumor tissue of 95 consecutive patients with adenocarcinoma of the lung was stained using a polyclonal c-kit antibody. c-kit expression was correlated with relevant clinical parameters obtained by chart review. Positive c-kit expression in tumor tissue was observed in 61 of 95 patients (64%). Univariate analysis showed a significant effect of T (p = 0.003), N (p = 0.001) and M stage (p < 0.001) as well as of performance status (p = 0.001), surgical resection (p < 0.001), and LDH serum levels (p = 0.016) on survival. In contrast, c-kit protein expression was non- significant (p = 0.913). However, multivariate Cox regression with the influential parameters revealed a significant effect of c-kit expression on survival. Forward stepwise selection showed a 1.77-fold increased risk to die (hazard ratio, HR; 95% confidence interval, CI: 1.00-3.14, p = 0.047) for patients with c-kit-positive tumors. Similar data for c-kit expression were obtained by backward stepwise selection (HR: 1.78; 95% CI: 1.00-3.16; p = 0.044). In conclusion, the receptor tyrosine kinase c-kit is frequently expressed in adenocarcinomas of the lung and has a relevant effect on patient survival. The results of this study support clinical trials targeting the c-kit receptor with specific c-kit inhibitors (e.g. imatinib).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1010-4283
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 2004 S. Karger AG, Basel.
|
| pubmed:issnType |
Print
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
235-42
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:15627886-Adenocarcinoma,
pubmed-meshheading:15627886-Aged,
pubmed-meshheading:15627886-Female,
pubmed-meshheading:15627886-Gene Expression Profiling,
pubmed-meshheading:15627886-Humans,
pubmed-meshheading:15627886-Lung Neoplasms,
pubmed-meshheading:15627886-Male,
pubmed-meshheading:15627886-Middle Aged,
pubmed-meshheading:15627886-Multivariate Analysis,
pubmed-meshheading:15627886-Prognosis,
pubmed-meshheading:15627886-Proto-Oncogene Proteins c-kit,
pubmed-meshheading:15627886-Retrospective Studies,
pubmed-meshheading:15627886-Survival Analysis
|
| pubmed:articleTitle |
c-kit expression in adenocarcinomas of the lung.
|
| pubmed:affiliation |
Institute of Legal Medicine and Rudolf Boehm Institute of Pharmacology and Toxicology, Leipzig, Germany. patrick.micke@licr.uu.se
|
| pubmed:publicationType |
Journal Article
|